section name header

Evidence summaries

Treatment for Barrett's Oesophagus

Endoscopic therapies might possibly induce regression of Barrett's oesophagus and dysplasia, although the evidence is insufficient. Level of evidence: "D"

A Cochrane review [Abstract] 1 included 16 studies with a total of 1 074 subjects. Medical and surgical interventions to reduce symptoms and sequelae of gastro-oesophageal reflux disease (GORD) did not induce significant eradication of Barrett's oesophagus or dysplasia. Endoscopic therapies (photodynamic therapy (PDT with aminolevulinic acid or porfimer sodium), argon plasma coagulation (APC) and radiofrequency ablation (RFA)) all induced regression of Barrett's oesophagus and dysplasia. The data for photodynamic therapy were heterogeneous with a mean eradication rate of 51% for Barrett's oesophagus and between 56% and 100% for dysplasia, depending on the treatment regimens. The variation in photodynamic therapy eradication rates for dysplasia was dependent on the drug, source and dose of light. Radiofrequency ablation resulted in eradication rates of 82% and 94% for Barrett's oesophagus and dysplasia respectively, compared to a sham treatment. Endoscopic treatments were generally well tolerated, however all were associated with some buried glands, particularly following argon plasma coagulation and photodynamic therapy, as well as photosensitivity and strictures induced by porfimer sodium based photodynamic therapy in particular.

Comment: The quality of evidence is downgraded by study quality (unclear allocation concealment and blinding), by inconsistency (heterogeneity in interventions and outcomes), and by imprecise results (limited study size for each comparison).

    References

    • Rees JR, Lao-Sirieix P, Wong A, Fitzgerald RC. Treatment for Barrett's oesophagus. Cochrane Database Syst Rev 2010;(1):CD004060. [PubMed]

Primary/Secondary Keywords